



SINTOMA'24

PARCERIA **soho**
society of hematologic oncology

APOIO
INSTITUCIONAL

bp Educação
e Pesquisa

Multidisciplinary Approach in the Transition from Hospital to Home Care

Maikel Valdes

DNP, APRN, AOCNP, CRNI

Objectives

Discuss the entities and disciplines involved in the transition to the Home Setting

Review the key aspects to evaluate an Oncology Treatment in the Home Setting

Review the common challenges patients experience in the home with chemotherapy and immunotherapy


Interdisciplinary Approach

Referring Physician/Acute Facility

Ancillary Services

- **Durable Medical Equipment**
- **Supplies**

Laboratory Entity



Home Health Care Agency

Home Infusion Pharmacy



Skilled Nursing

- Injections
- Wound Care
- Medication Management
- Ostomy Care
- Catheter Care
- Enteral Nutrition
- **Home Infusion**

Therapy Services

- Physical Therapy
- Occupational Therapy
- Speech Therapy

Home Health Aide

- Personal Care
- Assistance with Activities of Daily Living

Medical Social Worker

- Community Resources Planning and Outreach
- Long Term Planning and decision making
- Psychosocial Assessment

Home Infusion Services

- Antibiotic Therapy
- Antiviral Therapy
- Antifungal Therapy
- Total Parenteral Nutrition
- Inotropic Therapy
- Pain Management
- Hydration
- Immunoglobulin Therapy
- **Chemotherapy and Immunotherapy**

Infusion Pharmacists

- Patient Clinical Management (Assessment, Lab monitoring, Dosing, Education, Care Coordination with provider/nursing, On Call Services)

Infusion Pharmacy Technicians

- Prescription processing and compounding
- Shipping
- Inventory and Equipment Management
- Revenue Collection

Infusion Support

- Intake Staff
- Registered Nurses
- Purchasing and Logistics
- IT, Billing and Reporting

Home Infusion Workflow

Intake: Verification of Benefits and suitability for Home Health

Clinical Functions

- Clinical assessment, patient education & monitoring
- Pharmacy dosing & IV compounding
- 24/7 on-call access to pharmacist

Operational Functions

- Provide patient supplies & IV pumps
- Delivery to patient

Financial services

- Billing, collections, auditing, ...

Collaborate with providers & home care nursing

Why Oncology at Home?

Convenience for the patient and family

Eliminate significant travel for patients

Caregiver can fulfill their obligations

Privacy within the comfort of home



SINTOMA'24

PARCERIA **soho**
society of hematologic oncology

APOIO INSTITUCIONAL **bp** Educação e Pesquisa

Appropriate Oncology Patients for Home Care

Drug Regimen Profile

Proven Patient Tolerance & Stability

Insurance Type

Patient Geography

Acceptable Home Environment

Education and Training

Complete Chemotherapy Immunotherapy Certificate course from the Oncology Nursing Society (ONS)

Oncology Certified Nurse (OCN), preferred.

Most of the chemotherapy Registered Nurses (RN) have prior work experience in oncology infusion centers

Complete chemotherapy specific competency checklist before administering chemo in the home

Annual Ongoing Evaluations required

Competency: Core Content

- Types of treatment, classification of agents, and routes of administration
- Pharmacology of agents, regardless of indications for use
- Pertinent molecular biomarkers, including genomic assays
- Chemotherapy and radiotherapy protectants
- Principles of safe preparation, storage, labeling, transportation, administration and disposal of agents
- Procedures for safe handling of hazardous drugs including spill management
- Appropriate use and disposal of personal protective equipment
- Use of engineering controls and use of closed-system drug transfer devices
- Assessment, monitoring, and management of patients receiving therapy
- Medication safety and system safeguards, such as infusion pump safety features
- Appropriate procedures for emergency preparedness to include infusion reactions and extravasation
- Appropriate documentation of treatment administration, patient education, and planned follow-up care and testing
- Patient and family/caregiver education for these agent(s), specific to side effects and related symptom management, and processes for urgent and ongoing follow-up
- Education and coordination of post-treatment care and testing, adverse events, and long-term side effects, physical and psychosocial impacts of a cancer diagnosis and treatment, and follow up care during survivorship

Oncology Competency

To administer antineoplastic therapies, nursing staff must have Oncology Nurse Certification (ONC) or Oncology Nursing Society (ONS) Chemotherapy Immunotherapy Certificate

OCN Certification

- Certification exam requires 2,000 hours of oncology practice

ONS/ONCC Chemotherapy Immunotherapy Certificate

- Provides knowledge of antineoplastic therapy administration
- Requires nursing practice experience of 6 months or more

Availability of Qualified Nurses

Regimen Tracking using NCCN Guidelines for order templates and treatment schedule

Coordination of timely labs and results

Coordination of drug deliveries

Adverse effect management and antidotes

Key Aspects of Home Infusion Oncology

Schedule precision

Treatment cycle tracking

Mixing and independent double-checking

Adverse event management

Vesicant extravasation protocol, training, antidotes

Track dose accumulation for drugs with lifetime toxicity limits

Key Aspects of Home Infusion Oncology- Cont.

HD Policies

- Reproductive concerns
- Employee surveillance program
- Hazardous drug storage and handling
- Hazardous drug administration
- Handling spills
- Decontamination

Safety

- Engineered controls: OSHA–hazardous drug recommendations
- Exposure policies: ONS hazardous drug handling
- Training and certifications: OCN preferred, provider card minimum

Coordination

- Appointment reminder calls and tox screen before ordering meds
- Ensure routine MD follow ups
- Oncologist must be made aware of any toxicity or unresolved complications
- Oral complement meds and ancillary therapies likely with this population


Cancer care in the home seeing significant growth

1 Payer Site of Care Policies

- Significant differences in reimbursement rates across sites of care due to differences in facility fees, drug administration reimbursement & drug reimbursement
- Private payers have developed site of care policies with goal of shifting care away from HOPD setting for qualifying patients and treatments driving interest by hospitals / health systems to consider emerging sites such as the home

5 Limited Rural Access

- Rural cancer patients often face substantial barriers to receiving treatment
- Barriers include distance to services, availability of specialists, and lack of travel options; the home emerging as a site of care may improve access for such patients
- SDOC



4 Proliferation of Lower Toxicity Therapies

- Therapies that are viewed to have lower toxicity may add to the feasibility of shifting treatment site away from the hospital

2 Growth of Oral Therapies & Subcutaneous Therapies

- Oral and subcutaneous oncology treatments have grown faster than infused therapies
- Since 2015 over 60% of new active substances in cancer have been oral formulations, largely due to proliferation of PKIs with molecular and biomarker targets
- Oral and subcutaneous formulations largely allow for better quality of life and patient experience; additional autonomy and convenience for patients


3 Patient Demand

- Many patients prefer to stay in the home during cancer treatment
- ~72% of patients report being satisfied with home infusion and would recommend to family or friends

Multidisciplinary Evaluation of each Treatment

- Abraxane (paclitaxel protein bound)
- Adriamycin (doxorubicin)
- Adrucil (fluorouracil)
- Avastin & biosimilars (bevacizumab)
- Bavencio (avelumab)
- Blincyto (blinatumomab)
- Cytosan (cyclophosphamide)
- Dacarbazine (DTIC)
- Dacogen (decitabine)
- Darzalex (daratumumab) SQ/IV
- Doxil (doxorubicin liposome)
- Gemzar (gemcitabine)
- Herceptin & biosimilars (trastuzumab)
- Herceptin Hylecta (trastuzumab/hyaluronidase)
- Ifex (ifosfamide)
- Imfinzi (durvalumab)
- Kadcyla (ado-trastuzumab emtansine)
- Keytruda (pembrolizumab)
- Kyprolis (carfilzomib)
- Navelbine (vinorelbine)
- Oncovin (vincristine)
- Opdivo (nivolumab)
- Perjeta (pertuzumab)
- Phesgo (pertuzumab/trastuzumab) SQ
- Taxol (paclitaxel) continuous IV
- Velcade (bortezomib) SQ/IV
- Vidaza (azacitidine) SQ only
- Yervoy (ipilimumab)

Admission Process



We can do it!



Obrigado

Maikel Valdes

DNP, APRN, AOCNP, CRNI

m.oliva1@miami.edu